Cycle Pharmaceuticals announces the launch of PHYRAGO, its first oncology product in the US. PHYRAGO is launched in ...

Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Cycle ...

The US FDA has accepted the new drug application (NDA) for XS003, a formulation referencing the tyrosine kinase inhibitor (TKI) nilotinib (Tasigna), for treatment of chronic myeloid leukemia (CML). 1 ...

Leukemia is a cancer that changes blood cells. It usually develops in the bone marrow, the inner part of the bone that makes ...

When oral medicines for Chronic Myeloid Leukemia (CML) first became available, they dramatically changed what it meant to ...

Suboptimal response or treatment failure to standard-dose imatinib are relevant problems in chronic-phase chronic myeloid leukemia patients. Insufficient adherence is one of the main causes of ...

Healthcare Analysts discuss emerging therapies in chronic myeloid leukemia (CML), (relevant companies NVS, ENLV, TERN, TAK, BMY, PFE) on an ...